Drug Information Association Logo

Budget Impact Analysis of Tofacitinib for Treatment of Rheumatoid Arthritis

Time

Mon, Jun 16 7:45AM
M 05

Title

Budget Impact Analysis of Tofacitinib for Treatment of Rheumatoid Arthritis

Abstract Summary

A budget impact model (BIM) was developed from a US healthcare payer’s perspective, with one year time frame, using a hypothetical cohort of 1 million health plan enrollees and assuming a 0.5% RA prevalence. The BIM was tested for incident (scenario 1) and prevalent (scenario 2) anti-TNF users.

Poster Presenter

Rituparna Bhattacharya
MS,
Student,School of Pharmacy ,
West Virginia University
United States